Biopharma news, November 20, 2026
6 stories
In this digest: Approval 1 · Pivotal readout 2 · Licensing & partnership 2 · Clinical readout 1
Top stories
Anbirui Companion Diagnostic Approved
China's NMPA approved a companion diagnostic kit for Anbirui to detect EGFR exon 20 insertions in patients with non-small cell lung cancer. Anbirui received conditional NMPA drug approval in April 2026 for eligible adults previously treated with or intolerant to platinum-based chemotherapy. Anbirui was added to China's 2026 national reimbursement drug list, which takes effect on January 1, 2027.
Source types: Press release
Mangaciclanol Advances to Phase 3
GE HealthCare reported that mangaciclanol met the Phase 2 primary endpoint, with overall diagnostic preference similar to gadobutrol in central nervous system imaging.
Read more about Mangaciclanol Advances to Phase 3
The company selected a 0.1 mmol/kg dose for Phase 3; mangaciclanol was well tolerated in Phase 2, with no safety concerns identified. The investigational agent has FDA Fast Track designation. Preliminary Phase 2 results will be presented at RSNA 2026.
Source types: Press release
Boston Scientific Prices Note Offerings
Boston Scientific priced $3 billion in U.S. dollar-denominated notes, while its finance subsidiary priced €4.25 billion in euro-denominated notes.
Read more about Boston Scientific Prices Note Offerings
The company intends to use the proceeds, alongside other funding sources, primarily to finance the cash consideration for its proposed acquisition of Penumbra and related expenses. The offerings are expected to close on December 1, 2026. Except for the floating-rate notes, the notes are subject to special mandatory redemption if the acquisition does not proceed under specified conditions.
Source types: Press release
News in brief
TREMFYA improves axial PsA
Read more about TREMFYA improves axial PsA
In the 411-participant Phase 4 STAR study, TREMFYA improved axial disease activity versus placebo at week 24 in biologic-naïve adults with psoriatic arthritis and MRI-confirmed axial inflammation. Mean BASDAI scores fell by 3.3 and 2.9 points with four-weekly and eight-weekly TREMFYA, respectively, versus 2.1 with placebo. MRI-assessed sacroiliac inflammation also declined more with TREMFYA. No new safety signals were identified. The four-weekly regimen is not approved in the United States, and physical-function improvement with eight-weekly dosing did not reach statistical significance.
Source types: Press release · News article
SRX Updates T-Cell Strategy
Read more about SRX Updates T-Cell Strategy
SRX highlighted Pfizer's $330 million upfront licensing agreement with Starna as evidence of interest in engineered T-cell platforms, while noting that the deal is not a valuation benchmark for CERo. CERo has dosed seven patients in its ongoing Phase 1/1b CERTAIN-T trial of CER-1236; no dose-limiting toxicities were reported during assessment of the first three patients in the second cohort. SRX's proposed acquisition of CERo Therapeutics remains pending. The clinical findings are preliminary and do not establish CER-1236's safety or efficacy.
Source types: Press release
Sac-TMT Improves Overall Survival
Read more about Sac-TMT Improves Overall Survival
In the 473-patient phase 3 TroFuse-015 trial, sac-TMT significantly improved overall survival versus physician's-choice therapy after at least two prior systemic treatments. The trial did not meet its progression-free survival endpoint; the response-rate improvement was nominal and not formally tested. No new safety signals were reported. Merck plans to present detailed results at a medical meeting and share them with regulators; survival and response figures were not disclosed.
Source types: Press release
Sources are available to Gosset users. Log in to see them.
All digests
- November 19, 2026 6 stories
- November 18, 2026 5 stories
- November 17, 2026 5 stories
- November 16, 2026 3 stories
- November 15, 2026 4 stories
- November 14, 2026 5 stories
- November 13, 2026 5 stories
- November 12, 2026 10 stories
- November 11, 2026 10 stories
- November 10, 2026 10 stories
- November 9, 2026 10 stories
- November 8, 2026 9 stories
- November 7, 2026 7 stories
- November 6, 2026 10 stories
- November 5, 2026 10 stories